RESUMO
Pro-myelocytic acute leukemia (APL) is characterized by the proliferation of cells blocked at promyelocytic stage and ATRA is the choice of initial treatment because of the APL sensitivity to this compound. In this case study we report a 28-year-old man who presented to the Emergency Department with epistaxis, petechial rash, and fever. Laboratory tests revealed the presence of high white blood cell count with 60% blasts and evidence of coagulopathy. The diagnosis was confirmed later as APL. Because of the delayed transfer to the reference center and unavailability of ATRA initial treatment, the patient received isotretinoin, a related compound. The treatment was successfully implemented in the initial management of acute pro-myelocytic leukemia as patient condition improved. isotretinoin could be used as an alternative therapy for ATRA whenever the latter is not available. further research is needed to establish the appropriate doses and to assess the potential risk of differentiation syndromes.
RESUMO
BACKGROUND: Tumor budding (TB) is a promising prognostic factor in colorectal cancer (CRC) that is independent of tumor-node-metastasis (TNM) staging. Leucine-rich repeat-containing G-protein-coupled receptor 5 (Lgr5) is a stem cell marker and a member of the canonical Wnt-signaling cascade. It is involved in colorectal carcinogenesis. However, its role in CRC progression and TB needs to be clarified. MATERIALS AND METHODS: TB was assessed in both H and E and CK immunostained sections of 92 CRC cases. Associations between TB grade and different clinicopathological parameters were evaluated. Lgr5 expression in CRC cases and its association with TB grade and other clinicopathological features was also evaluated. RESULTS: H and E stained sections revealed low- and high-grade budding in 55 (59.8%) and 37 (40.2%) tumors, respectively, whereas Cytokeratin Immunohistochemistry (CK-IHC) showed low- and high-grade budding in 31 (33.7%) and 61 (66.3%) tumors, respectively. TB grade (in H and E and CK stained sections) was significantly associated with adverse pathological prognostic variables including vascular invasion (P = 0.03 and 0.001), lymph node metastasis (P = 0.001 and 0,001), advanced Dukes (P = 0.000 and 0.000), and TNM (P = 0.001 and 0.000) stages and inversely associated with Tumor infiltrating lymphocytes (TILS) (P = 0.02 and 0.0001) which is known to be a good prognostic indicator. Lgr5 protein was positively expressed in 52.2% (48/92) of the CRCs. Immunoreactivity of Lgr5 was significantly associated with histological grade (P = 0.01), lymph node metastasis (P = 0.002), vascular invasion (P = 0.02), TNM stage (P = 0.000), Dukes stage (P = 0.000), and TILS (P = 0.03). Furthermore, Lgr5 was found to be significantly associated with TB estimated in both H and E and CK stained tumors (P = 0.003 and 0.001 respectively). CONCLUSION: This study supported the relevance of TB in the assessment of CRC aggressiveness. It also revealed that Lgr5 expression is related to morphologic features in the invasive front of CRC. Lgr5 could have an important role in forming a morphologic feature at the invasive front associated with the aggressiveness of the tumor.
Assuntos
Adenocarcinoma/genética , Neoplasias Colorretais/patologia , Células-Tronco Neoplásicas/patologia , Receptores Acoplados a Proteínas G/genética , Adenocarcinoma/patologia , Adolescente , Adulto , Idoso , Biomarcadores Tumorais , Neoplasias Colorretais/genética , Feminino , Estudos de Associação Genética , Humanos , Imuno-Histoquímica , Metástase Linfática , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Retrospectivos , Adulto JovemAssuntos
Neoplasias do Mediastino/diagnóstico , Neoplasias do Mediastino/patologia , Melanoma/diagnóstico , Melanoma/patologia , Biomarcadores Tumorais/análise , Feminino , Histocitoquímica , Humanos , Imuno-Histoquímica , Imageamento por Ressonância Magnética , Neoplasias do Mediastino/diagnóstico por imagem , Microscopia , Radiografia Torácica , Proteínas S100/análise , Adulto JovemRESUMO
Primary thyroid lymphoma (PTL) is a rare disorder accounting for about 2 % of all malignant lymphomas. It is an aggressive extranodal non Hodgkin lymphoma mostly of B lineage. We report four cases of PTL and highlight the clinical issues and challenges posed by this rare disease.
RESUMO
We present a brief review of a rare entity, May Hegglin anomaly. We also put forth a few pictures characterizing it.